Michael A Gillette,Shankha Satpathy,Song Cao,Saravana M Dhanasekaran,Suhas V Vasaikar,Karsten Krug,Francesca Petralia,Yize Li,Wen-Wei Liang,Boris Reva,Azra Krek,Jiayi Ji,Xiaoyu Song,Wenke Liu,Runyu Hong,Lijun Yao,Lili Blumenberg,Sara R Savage,Michael C Wendl,Bo Wen,Kai Li,Lauren C Tang,Melanie A MacMullan,Shayan C Avanessian,M Harry Kane,Chelsea J Newton,MacIntosh Cornwell,Ramani B Kothadia,Weiping Ma,Seungyeul Yoo,Rahul Mannan,Pankaj Vats,Chandan Kumar-Sinha,Emily A Kawaler,Tatiana Omelchenko,Antonio Colaprico,Yifat Geffen,Yosef E Maruvka,Felipe da Veiga Leprevost,Maciej Wiznerowicz,Zeynep H Gümüş,Rajwanth R Veluswamy,Galen Hostetter,David I Heiman,Matthew A Wyczalkowski,Tara Hiltke,Mehdi Mesri,Christopher R Kinsinger,Emily S Boja,Gilbert S Omenn,Arul M Chinnaiyan,Henry Rodriguez,Qing Kay Li,Scott D Jewell,Mathangi Thiagarajan,Gad Getz,Bing Zhang,David Fenyö,Kelly V Ruggles,Marcin P Cieslik,Ana I Robles,Karl R Clauser,Ramaswamy Govindan,Pei Wang,Alexey I Nesvizhskii,Li Ding,D R Mani,Steven A Carr,Clinical Proteomic Tumor Analysis Consortium,Alex Webster,Alicia Francis,Alyssa Charamut,Amanda G Paulovich,Amy M Perou,Andrew K Godwin,Andrii Karnuta,Annette Marrero-Oliveras,Barbara Hindenach,Barbara Pruetz,Bartosz Kubisa,Brian J Druker,Chet Birger,Corbin D Jones,Dana R Valley,Daniel C Rohrer,Daniel Cui Zhou,Daniel W Chan,David Chesla,David J Clark,Dmitry Rykunov,Donghui Tan,Elena V Ponomareva,Elizabeth Duffy,Eric J Burks,Eric E Schadt,Erik J Bergstrom,Eugene S Fedorov,Ewa Malc,George D Wilson,Hai-Quan Chen,Halina M Krzystek,Hongwei Liu,Houston Culpepper,Hua Sun,Hui Zhang,Jacob Day,James Suh,Jeffrey R Whiteaker,Jennifer Eschbacher,John McGee,Karen A Ketchum,Karin D Rodland,Karna Robinson,Katherine A Hoadley,Kei Suzuki,Ki Sung Um,Kim Elburn,Liang-Bo Wang,Lijun Chen,Linda Hannick,Liqun Qi,Lori J Sokoll,Małgorzata Wojtyś,Marcin J Domagalski,Marina A Gritsenko,Mary B Beasley,Matthew E Monroe,Matthew J Ellis,Maureen Dyer,Meghan C Burke,Melissa Borucki,Meng-Hong Sun,Michael H Roehrl,Michael J Birrer,Michael Noble,Michael Schnaubelt,Michael Vernon,Michelle Chaikin,Mikhail Krotevich,Munziba Khan,Myvizhi Esai Selvan,Nancy Roche,Nathan J Edwards,Negin Vatanian,Olga Potapova,Pamela Grady,Peter B McGarvey,Piotr Mieczkowski,Pushpa Hariharan,Rashna Madan,Ratna R Thangudu,Richard D Smith,Robert J Welsh,Robert Zelt,Rohit Mehra,Ronald Matteotti,Sailaja Mareedu,Samuel H Payne,Sandra Cottingham,Sanford P Markey,Seema Chugh,Shaleigh Smith,Shirley Tsang,Shuang Cai,Simina M Boca,Sonya Carter,Stacey Gabriel,Stephanie De Young,Stephen E Stein,Sunita Shankar,Tanya Krubit,Tao Liu,Tara Skelly,Thomas Bauer,Uma Velvulou,Umut Ozbek,Vladislav A Petyuk,Volodymyr Sovenko,William E Bocik,William W Maggio,Xi Chen,Yan Shi,Yige Wu,Yingwei Hu,Yuxing Liao,Zhen Zhang,Zhiao Shi

Abstract:To explore the biology of lung adenocarcinoma (LUAD) and identify new therapeutic opportunities, we performed comprehensive proteogenomic characterization of 110 tumors and 101 matched normal adjacent tissues (NATs) incorporating genomics, epigenomics, deep-scale proteomics, phosphoproteomics, and acetylproteomics. Multi-omics clustering revealed four subgroups defined by key driver mutations, country, and gender. Proteomic and phosphoproteomic data illuminated biology downstream of copy number aberrations, somatic mutations, and fusions and identified therapeutic vulnerabilities associated with driver events involving KRAS, EGFR, and ALK. Immune subtyping revealed a complex landscape, reinforced the association of STK11 with immune-cold behavior, and underscored a potential immunosuppressive role of neutrophil degranulation. Smoking-associated LUADs showed correlation with other environmental exposure signatures and a field effect in NATs. Matched NATs allowed identification of differentially expressed proteins with potential diagnostic and therapeutic utility. This proteogenomics dataset represents a unique public resource for researchers and clinicians seeking to better understand and treat lung adenocarcinomas.

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 3 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Figure 1 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1.

Supplementary Table 1 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

A proteogenomic portrait of lung squamous cell carcinoma

Table S1, S2, S3 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

Supplementary Table 7 from Comparative Oncogenomics Identifies PSMB4 and SHMT2 as Potential Cancer Driver Genes

Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies

Proteomic Stratification of Prognosis and Treatment Options for Small Cell Lung Cancer

Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma

Comprehensive Genomic Profiles of Small Cell Lung Cancer

Supplementary Tables 1 - 3 from Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer

Supplementary Table 1 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Supplemental Tables from Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer

Supplemental Methods and Legends from Target Identification in Small Cell Lung Cancer Via Integrated Phenotypic Screening and Activity-Based Protein Profiling

Table S14 from Activation of PI3K/AKT Pathway is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer